Creating the ideal immunotherapy
Inducing a Broad
Cancer Stem Cells
Vaxil’s Lead Products and Orphan Drug Status
Vaxil believes its immunotherapy platform allows it to target high profile cancer antigens in a uniquely superior manner, all designed to possess the novel advantages described above. Vaxil’s first test of its VaxHit™ platform is its Immucin™; lead immunotherapy product.
Immunotherapy has become the most promising field in the fight against cancer. Whereas chemotherapy was once seen as a breakthrough and still utilized successfully in many patients, today’s scientists recognize immunotherapy is the way of the future. Learn More
VAXIL’S PRIMARY PLATFORM GENERATES COMPREHENSIVE IDENTIFICATION, ISOLATION & PRODUCTION OF ANTIGEN-SPECIFIC IMMUNOTHERAPIES Vaxil’s VaxHit™ platform technology combines proprietary algorithms which enable in-silico identification of signal peptides domains and their subsequent use as immunotherapeutic products. The VaxHit™ platform is essentially a launchpad for novel and uniquely targeted immunotherapy products. Learn More